Skip Navigation



NDT Advance Access published online on October 18, 2005
Nephrology Dialysis Transplantation, doi:10.1093/ndt/gfi230
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
21/2/397    most recent
gfi230v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sinico, R. A.
Right arrow Articles by Bollini, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sinico, R. A.
Right arrow Articles by Bollini, B.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org
Received August 2, 2005
Accepted September 27, 2005

Original Articles

Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: comparison of different assays

Renato Alberto Sinico 1*, Antonella Radice 1, Caterina Corace 2, Ettore Sabadini 1, and Bruna Bollini 2

1 Unità Operativa di Immunologia Clinica, Dipartimento Area Medica e Dipartimento di Nefrologia e Immunologia, Azienda Ospedaliera Ospedale San Carlo Borromeo
2 Fondazione D'Amico per la Ricerca in Nefrologia, Milano, Italy

* To whom correspondence should be addressed.
Renato Alberto Sinico, E-mail: renatoalberto.sinico{at}fastwebnet.it



  Abstract

Background. The role of anti-glomerular basement membrane (GBM) antibodies in the pathogenesis of Goodpasture syndrome (GPS) is firmly established. Untreated, the disease may follow a fulminating course. Early identification of patients has important implications in terms of management and prognosis. Therefore, a diagnostic test for the determination of circulating anti-GBM antibodies, of very high sensitivity and specificity, is necessary. A number of assays, using different antigenic substrates, are available, but studies comparing the ‘performances’ of the different tests are scarce.

Methods. The aim of our work was to evaluate the sensitivity and specificity of four immunoassay-based anti-GBM antibodies kits. Thirty-four serum samples from 19 GPS patients, 41 pathological and 28 normal controls were studied retrospectively (the follow-up samples were not included in the analysis of performance data). Cut-off limits were derived from receiver operating characteristics curve analysis.

Results. All the assays showed a comparable good sensitivity (between 94.7 and 100.0%), whereas specificity varied considerably (from 90.9 to 100.0%). The better performance in terms of sensitivity/specificity was achieved by a fluorescence immunoassay which utilizes a recombinant antigen.

Conclusion. All the assays have a good performance, with high sensitivity; however, the specificity may vary considerably.

Keywords: anti-glomerular basement membrane (GBM) antibodies; anti-GBM disease; ELISA; Goodpasture syndrome; NC1 portion of the {alpha}3 chain of type IV collagen.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Nephrol Dial TransplantHome page
M. Ruster, M. Kiehntopf, H.-J. Grone, and G. Wolf
A Friday afternoon case of apparent anti-glomerular basement nephritis
Nephrol. Dial. Transplant., August 1, 2006; 21(8): 2328 - 2330.
[Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.